L&K Biomed Reports Operating Profit of 2.45 Billion KRW in Q3... 'Strong Sales of New Products'
[Asia Economy Reporter Hyungsoo Park] L&K Biomed, a specialist company in spinal implants, announced on the 3rd that it recorded an operating profit of 2.45 billion KRW in the third quarter of this year, turning profitable compared to the same period last year.
Sales increased by 60.88% compared to the same period last year, reaching 6.58 billion KRW. Net profit also turned positive, recording 2.42 billion KRW. The improved performance is attributed to the full-scale entry of the new product, the Expandable Cage, into the US market.
A representative from L&K Biomed explained, "Since the third quarter of this year, sales of the posterior insertion height-adjustable intervertebral body fusion device ‘AccelFix-XT’ have begun," adding, "The increase in sales and the decrease in cost ratio led to the successful turnaround to profitability."
They continued, "We expect the trend of performance improvement to continue beyond the fourth quarter of this year," and forecasted, "With the operation of the second factory at the end of February next year and the launch of new products additionally approved by the FDA, the speed of performance improvement will accelerate."
L&K Biomed holds patents related to spinal implant medical devices spanning from the upper to the lower spine. Recognized for its technological capabilities in the US market, the company has obtained FDA product approvals for three types of spinal implant products used in the lumbar region: Posterior approach, Lateral approach, and Oblique Lateral approach.
The company is focusing on developing products applicable to all approaches other than the existing ones, as well as cervical implant products. They plan to additionally introduce height-adjustable cages for the anterior approach used in the lumbar spine and height-adjustable cages for the cervical spine to the US market.
Hot Picks Today
"Buy on Black Monday"... Japan's Nomura Forecasts 590,000 for Samsung, 4 Million for SK hynix
- "Not Everyone Can Afford This: Inside the World of the True Top 0.1% [Luxury World]"
- "Plunged During the War, Now Surging Again"... The Real Reason Behind the 6% One-Day Silver Market Rally [Weekend Money]
- Key Figures Jo Taeyong and Kim Yonghyun to Receive First Trial Verdicts Next Week in "December 3 Martial Law" Case... Special Prosecutor’s Results Expected
- Experts Are Already Watching Closely..."Target Stock Price 970,000 Won" Now Only the Uptrend Remains [Weekend Money]
Recently, L&K Biomed has formed partnerships with global medical device manufacturers, distributors, and sales companies. Preparing for an increase in export volume, they are constructing a second factory in Daewoo Frontier Valley, Yongin-si, Gyeonggi-do, aiming for completion early next year.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.